These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 31182597)

  • 1. Correction for Lorenzo et al., Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12572. PubMed ID: 31182597
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical characteristics of bladder urothelial tumors in male patients--the influences of benign prostatic hyperplasia/benign prostatic enlargement.
    Zhang NZ; Chen J; Ma L; Xu ZS
    Urol Oncol; 2012 Sep; 30(5):646-51. PubMed ID: 20870428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of inflammation in benign prostatic hyperplasia development among Han Chinese: A population-based and single-institutional analysis.
    Hu J; Zhang L; Zou L; Hu M; Fan J; Cai Y; Xu G; Fang J; Ding Q; Jiang H
    Int J Urol; 2015 Dec; 22(12):1138-42. PubMed ID: 26311564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia.
    Renko O; Savolainen ER; Loikkanen I; Paavonen TK; Vaarala MH
    DNA Cell Biol; 2008 Feb; 27(2):109-13. PubMed ID: 17979523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia.
    Pelton K; Di Vizio D; Insabato L; Schaffner CP; Freeman MR; Solomon KR
    J Urol; 2010 Oct; 184(4):1555-9. PubMed ID: 20728125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
    Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    Am J Med; 1998 Jun; 104(6):517-25. PubMed ID: 9674713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?
    Shimizu S; Tsounapi P; Shimizu T; Honda M; Inoue K; Dimitriadis F; Saito M
    Int J Urol; 2014 Sep; 21(9):856-64. PubMed ID: 24930630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
    Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ; Moreira DM
    J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
    Parsons JK; Sarma AV; McVary K; Wei JT
    J Urol; 2013 Jan; 189(1 Suppl):S102-6. PubMed ID: 23234610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
    Parsons JK; Sarma AV; McVary K; Wei JT
    J Urol; 2009 Dec; 182(6 Suppl):S27-31. PubMed ID: 19846130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
    Goel MM; Agrawal D; Natu SM; Goel A
    Indian J Pathol Microbiol; 2011; 54(3):476-81. PubMed ID: 21934206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
    Hu XY; Xu YM; Chen XC; Ping H; Chen ZH; Zeng FQ
    APMIS; 2006 Dec; 114(12):893-8. PubMed ID: 17207090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White blood cell count is positively associated with benign prostatic hyperplasia.
    Fujita K; Hosomi M; Nakagawa M; Tanigawa G; Imamura R; Uemura M; Nakai Y; Takayama H; Yamaguchi S; Nonomura N
    Int J Urol; 2014 Mar; 21(3):308-12. PubMed ID: 23980666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectal invasion by benign prostatic hyperplasia.
    Herr HW; Whitmore WF; Lieberman PH; Grabstald H
    J Urol; 1977 Sep; 118(3):497-9. PubMed ID: 71362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Weiss N; Goodman P; Antvelink CM; Penson DF; Thompson IM
    J Urol; 2007 Apr; 177(4):1395-400; quiz 1591. PubMed ID: 17382740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.